Answers are grounded in this paper and cite their sources.
Herein, we report a facile strategy to prepare supported lipid-bilayer-coated polyacrylic acid/calcium phosphate nanoparticles (designated as PAA/CaP@SLB NPs) as a new dual pH-responsive drug-delivery platform for cancer chemotherapy. The synthesized PAA/CaP NPs exhibited both a high payload of doxorubicin (DOX) and dual pH-responsive drug-release properties. Additionally, the coated lipid bilayer had the ability to enhance the cellular uptake of PAA/CaP NPs without affecting the pH-responsive drug release. Moreover, the blank PAA/CaP@SLB NPs exhibited excellent biocompatibility and the DOX-loaded PAA/CaP@SLB NPs markedly increased the cellular accumulation of DOX and its cytotoxic effects on HepG-2 cells. Furthermore, when used to evaluate the in vivo therapeutic efficacy in mice with the hepatocarcinoma cell line (H-22), the DOX-loaded PAA/CaP@SLB NPs exhibited superior inhibition of tumor growth compared with the free DOX group. Thus, PAA/CaP@SLB NPs are a promising drug-delivery vehicle to increase the therapeutic efficacy of anticancer drugs.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: